Free Trial
→ Financial Legend: “Big trouble ahead …” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ONCY

Oncolytics Biotech Q3 2026 Earnings Date & Estimates

Oncolytics Biotech logo
$0.41 +0.02 (+5.13%)
As of 11:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Oncolytics Biotech is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Oncolytics Biotech in Q3 2026

Oncolytics Biotech is expected to post earnings of -$0.0539 per share. In the same quarter a year earlier Oncolytics Biotech reported -$0.10 per share. Oncolytics Biotech last reported on August 12, 2026, posting -$0.08 per share and missing the -$0.0538 consensus estimate. Oncolytics Biotech has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0539
Prior-Year EPS
-$0.10

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.08 (Missed by -$0.0262)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Oncolytics Biotech Q3 2026 Earnings FAQ

Oncolytics Biotech (NASDAQ:ONCY) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Oncolytics Biotech's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Oncolytics Biotech to post earnings of -$0.0539 per share for Q3 2026.

Oncolytics Biotech Earnings Headlines

Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395466/0/en/translational-data-from-anal-cancer-patients-show-pelareorep-drives-hpv-specific-immune-responses-supporting-its-potential-across-hpv-driven-cancers.html
Oncolytics Biotech Reports Durable Responses in GOBLET Cohort 4 Anal Cancer Study and Advances Pelareorep Toward Registration
October 27, 2026  |  quiverquant.comQ
Does your nest egg have an expiration date?
A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start with $150,000 and it's gone in under six years. A new Prudential survey of more than 3,000 Americans over 50 found 86% don't feel free to spend their savings on things they enjoy. Tim Plaehn, who has advised investors since the 1980s, is tracking a monthly income fund built on major U.S. companies that pays cash without requiring investors to sell shares.tc pixel
November 4 at 1:00 AM  |  Investors Alley (Ad)
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
October 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389148/0/en/oncolytics-biotech-reports-strong-durability-and-survival-data-in-anal-cancer-positioning-pelareorep-as-potential-backbone-immunotherapy-across-hpv-driven-cancers.html
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384572/0/en/oncolytics-biotech-to-present-reo-033-trial-in-progress-abstract-at-esmo-showcasing-pelareorep-s-potential-in-colorectal-cancer.html
Oncolytics Updates GOBLET Study Data Timelines, Expects Final PanCAN Grant Payment
October 14, 2026  |  rttnews.comhttps://www.rttnews.com/3699010/oncolytics-updates-goblet-study-data-timelines-expects-final-pancan-grant-payment.aspx
See More Oncolytics Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email.

About Oncolytics Biotech

Oncolytics Biotech (NASDAQ:ONCY) is a clinical-stage biotechnology company developing immunotherapies for cancer. The company’s lead product candidate is pelareorep, an investigational, intravenously delivered reovirus designed to selectively infect and destroy certain tumor cells while stimulating an immune response against cancer.

Oncolytics is evaluating pelareorep in combination with other cancer treatments, including chemotherapy, hormonal therapies and immune checkpoint inhibitors. Its research has focused primarily on breast cancer and gastrointestinal cancers, including pancreatic cancer, with development programs intended to assess the therapy’s potential across multiple tumor types.

Founded in 1998, Oncolytics Biotech is headquartered in Calgary, Alberta, and conducts clinical and corporate activities in North America and other regions through its research and development programs. The company is led by President and Chief Executive Officer Matt Coffey, Ph.D. Its common shares trade on the Nasdaq Capital Market under the symbol ONCY and on the Toronto Stock Exchange under the symbol ONC.

View Oncolytics Biotech Profile
Earnings Tools